Athena Athena

X

Find Drugs in Development News & Deals for Omeprazole Magnesium

PharmaCompass
API SUPPLIERS
API Suppliers

API Suppliers

US DMFs Filed

US DMFs Filed

CEP/COS Certifications

CEP/COS Certifications

JDMFs Filed

JDMFs Filed

0

Other Certificates

Other Certificates

Other Suppliers

Other Suppliers

API REF. PRICE (USD / KG)
235
INTERMEDIATES

0

DOSSIERS // FDF
USA (Orange Book)

USA (Orange Book)

Europe

Europe

Canada

Canada

Australia

Australia

0

South Africa

South Africa

0

Uploaded Dossiers

Uploaded Dossiers

GLOBAL SALES (USD Million)

U.S. Medicaid

Annual Reports

0

EXCIPIENTS
PATENTS & EXCLUSIVITIES

USFDA Orange Book Patents

USFDA Exclusivities

DIGITAL CONTENT

Blog #PharmaFlow

News

REF STANDARD

EDQM

USP

JP

0

Other Listed Suppliers

SERVICES
left grey arrow
right gray arrow
  • TABLET, DELAYED RELEASE;ORAL - EQ 20MG BASE
  • FOR SUSPENSION, DELAYED RELEASE;ORAL - EQ 10MG BASE/PACKET
  • FOR SUSPENSION, DELAYED RELEASE;ORAL - EQ 2.5MG BASE/PACKET

Details:

Omeprazole magnesium is a proton-pump inhibitor, used to treat gastric acid-related disorders. These disorders may include gastroesophageal reflux disease (GERD), peptic ulcer disease, and other diseases characterized by the oversecretion of gastric acid.


Lead Product(s): Omeprazole Magnesium

Therapeutic Area: Gastroenterology Product Name: Omeprazole Magnesium-Generic

Highest Development Status: ApprovedProduct Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable November 25, 2022

Prague Scientific Banner

Biotechgate Digital

Not Confirmed

envelop Contact Supplier

Details:

Talicia is a novel, fixed-dose, all-in-one oral capsule combination of two antibiotics (amoxicillin and rifabutin) and a proton pump inhibitor (PPI) (omeprazole), approved by the U.S. FDA for the treatment of H. pylori infection in adults.


Lead Product(s): Omeprazole Magnesium,Amoxicillin Trihydrate,Rifabutin

Therapeutic Area: Infections and Infectious Diseases Product Name: Talicia

Highest Development Status: ApprovedProduct Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable September 18, 2023

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

Talicia (omeprazole magnesium, amoxicillin and rifabutin) is a novel, fixed-dose, all-in-one oral capsule combination of two antibiotics and a proton pump inhibitor (PPI) (omeprazole), used for the treatment of H. pylori infection.


Lead Product(s): Omeprazole Magnesium,Amoxicillin Trihydrate,Rifabutin

Therapeutic Area: Infections and Infectious Diseases Product Name: Talicia

Highest Development Status: ApprovedProduct Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable August 01, 2023

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

Under the agreement, RedHill will make Talicia, a novel, all-in-one oral capsule combination of two antibiotics (amoxicillin and rifabutin) and a proton pump inhibitor (omeprazole magnesium), approved for H. pylori infection, available via the PhilRx Patient Access Platform.


Lead Product(s): Omeprazole Magnesium,Amoxicillin Trihydrate,Rifabutin

Therapeutic Area: Infections and Infectious Diseases Product Name: Talicia

Highest Development Status: ApprovedProduct Type: Small molecule

Partner/Sponsor/Collaborator: Phil

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Agreement July 06, 2023

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

Omeprazole Magnesium Delayed-Release Mini Capsules, 20 mg over-the-counter (OTC),represents a first-to-market mini capsule form of omeprazole, which is indicated for treatment of frequent heartburn.


Lead Product(s): Omeprazole Magnesium

Therapeutic Area: Gastroenterology Product Name: Omeprazole Magnesium-Generic

Highest Development Status: ApprovedProduct Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable May 26, 2022

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

Talicia (Omeprazole Magnesium) efficacy and safety profile evaluated in patients with H. pylori infection and diabetes mellitus, a large and challenging patient population associated with sub-optimal outcomes with clarithromycin-based H. pylori eradication therapy.


Lead Product(s): Omeprazole Magnesium,Amoxicillin Trihydrate,Rifabutin

Therapeutic Area: Infections and Infectious Diseases Product Name: Talicia

Highest Development Status: ApprovedProduct Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable May 25, 2022

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

Gaelan Medical will receive the exclusive rights to commercialize Talicia in the UAE, as well as a right of rst refusal to [1] 1 commercialize Talicia in the Gulf Cooperation Council region (Saudi Arabia, Kuwait, Qatar, Bahrain and Oman) for a pre-determined period.


Lead Product(s): Omeprazole Magnesium,Amoxicillin Trihydrate,Rifabutin

Therapeutic Area: Infections and Infectious Diseases Product Name: Talicia

Highest Development Status: ApprovedProduct Type: Small molecule

Partner/Sponsor/Collaborator: Gaelan Medical

Deal Size: Undisclosed Upfront Cash: $2.0 million

Deal Type: Licensing Agreement January 06, 2022

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

Talicia is designed to address the high resistance of H. pylori bacteria to historical standard-of-care therapies. Talicia® is a novel, fixed-dose, all-in-one oral capsule combination of two antibiotics (amoxicillin and rifabutin) with omeprazole magnesium.


Lead Product(s): Omeprazole Magnesium,Amoxicillin Trihydrate,Rifabutin

Therapeutic Area: Infections and Infectious Diseases Product Name: Talicia

Highest Development Status: ApprovedProduct Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable October 12, 2021

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

Talicia is designed to address the high resistance of H. pylori bacteria to historical standard-of-care therapies. Talicia® is a novel, fixed-dose, all-in-one oral capsule combination of two antibiotics (amoxicillin and rifabutin) with omeprazole magnesium.


Lead Product(s): Omeprazole Magnesium,Amoxicillin Trihydrate,Rifabutin

Therapeutic Area: Infections and Infectious Diseases Product Name: Talicia

Highest Development Status: ApprovedProduct Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable October 06, 2021

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

Pursuant to the agreement, the companies will co-develop a novel next-generation therapy for the eradication of H. pylori infection. Cosmo is to receive the exclusive European rights to the new drug.


Lead Product(s): Omeprazole Magnesium,Amoxicillin Trihydrate,Rifabutin

Therapeutic Area: Infections and Infectious Diseases Product Name: Talicia

Highest Development Status: ApprovedProduct Type: Small molecule

Partner/Sponsor/Collaborator: Cosmo Pharmaceuticals

Deal Size: $21.0 million Upfront Cash: Undisclosed

Deal Type: Licensing Agreement August 13, 2020

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

The non-dilutive financing will support the acquisition of rights to Movantik® from AstraZeneca, the planned U.S. launch of Talicia® this quarter and the ongoing promotion of Aemcolo®.


Lead Product(s): Omeprazole Magnesium,Amoxicillin Trihydrate,Rifabutin

Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

Highest Development Status: ApprovedProduct Type: Small molecule

Partner/Sponsor/Collaborator: HealthCare Royalty Partners

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Financing February 25, 2020

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

RedHill provided a notice of termination to Entera Health regarding the license agreement for EnteraGam® and the co-promotion agreement with Advanz Pharma Corp. for Donnatal® will not be renewed.


Lead Product(s): Omeprazole Magnesium,Amoxicillin Trihydrate,Rifabutin

Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

Highest Development Status: ApprovedProduct Type: Small molecule

Partner/Sponsor/Collaborator: Entera Health

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Termination Agreement January 21, 2020

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty
Post Enquiry
POST ENQUIRY